ABBV Financials AbbVie

12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 29 h ago Overview →

Growth & profitability

Revenue has grown 6.0% per year over the past 5 years.
Net income has grown slower than revenue (-1.7% vs 6.0% per year).
Operating margin has been roughly flat, at 24.6% in the latest year.
Free cash flow has grown 1.2% per year over the past 5 years.

Financial health

Total debt ($67.0B) exceeds cash ($5.2B); net debt is $61.8B.
Total debt has grown slower than revenue (-4.6% vs 6.0% per year).
Operating income covered interest expense 5.2× in the latest year, up from 4.6× 5 years ago.
Total debt is 4.4× EBITDA.

Shareholder returns

Dividends have been paid for 12 consecutive years, consuming 275.8% of earnings and 65.4% of free cash flow.
The dividend has grown 8.6% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$61.2B	$4.2B	70.2%	24.6%	$17.8B	$67.0B	$5.2B
2024	$56.3B	$4.3B	70.0%	16.2%	$17.8B	$66.8B	$5.5B
2023	$54.3B	$4.9B	62.4%	23.5%	$22.1B	$59.2B	$12.8B
2022	$58.1B	$11.8B	70.0%	31.2%	$24.2B	$63.1B	$9.2B
2021	$56.2B	$11.5B	69.0%	31.9%	$22.0B	$76.0B	$9.7B
2020	$45.8B	$4.6B	66.4%	24.8%	$16.8B	$85.0B	$8.4B
2019	$33.3B	$7.9B	77.6%	39.0%	$12.8B	$67.2B	$39.9B
2018	$32.8B	$5.7B	76.4%	19.5%	$12.8B	—	$7.3B
2017	$28.2B	$5.3B	75.0%	33.8%	$9.4B	—	$9.3B
2016	$25.6B	$6.0B	77.3%	36.4%	—	—	$5.1B
2015	—	$5.1B	—	—	—	—	$8.4B
2014	—	$1.8B	—	—	—	—	$8.3B

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Mar '26	$15.0B	$695M	71.9%	26.6%	$3.6B	—	$9.4B
Dec '25	$16.6B	$1.8B	72.6%	27.3%	$4.9B	$67.0B	$5.2B
Sep '25	$15.8B	$186M	66.4%	12.1%	$6.6B	—	$5.6B
Jun '25	$15.4B	$938M	71.8%	31.7%	$4.9B	—	$6.5B
Mar '25	$13.3B	$1.3B	70.0%	28.0%	$1.4B	—	$5.2B
Dec '24	$15.1B	-$22M	70.9%	-9.9%	$6.8B	$66.8B	$5.5B
Sep '24	$14.5B	$1.6B	70.9%	26.5%	$5.2B	—	$7.3B
Jun '24	$14.5B	$1.4B	70.9%	27.6%	$2.0B	—	$13.1B
Mar '24	$12.3B	$1.4B	66.7%	22.7%	$3.8B	—	$18.1B
Dec '23	$14.3B	$822M	60.1%	22.3%	$4.5B	$59.2B	$12.8B
Sep '23	$13.9B	$1.8B	53.4%	16.4%	$7.4B	—	$13.3B
Jun '23	$13.9B	$2.0B	69.4%	32.5%	$6.1B	—	$8.8B
Mar '23	$12.2B	$239M	67.4%	22.6%	$4.0B	—	$6.7B
Dec '22	$15.1B	$2.5B	72.4%	36.4%	$7.2B	$63.1B	$9.2B
Sep '22	$14.8B	$3.9B	66.1%	31.1%	$7.4B	—	$11.8B
Jun '22	$14.6B	$924M	71.4%	22.6%	$4.9B	—	$8.5B
Mar '22	$13.5B	$4.5B	70.1%	34.8%	$4.7B	—	$6.1B
Dec '21	$14.9B	$4.0B	71.0%	34.1%	$4.9B	$76.0B	$9.7B
Sep '21	$14.3B	$3.2B	69.4%	30.0%	$7.7B	—	$12.2B
Jun '21	$14.0B	$766M	67.6%	31.8%	$4.7B	—	$8.5B

Valuation over time

How the market has priced ABBV against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has risen from 23.8× (Mar '23) to 101.7× (Jun '26).
The price-to-sales ratio has risen from 4.8× (Mar '23) to 7.0× (Jun '26).
The dividend yield has fallen from 3.6% (Mar '23) to 2.7% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is ABBV growing its revenue and profit?

Over the past 5 years, AbbVie's revenue has grown 6.0% per year, and net income declined 1.7% per year. These are computed facts, not advice.

How much debt does ABBV have?

As of FY2025, AbbVie reported $67.0B of total debt against $5.2B of cash; operating income covered interest expense 5.2×.

What is ABBV's profit margin?

In FY2025, gross margin was 70.2%, operating margin 24.6%, and net margin 6.9%.

What is ABBV's P/E ratio?

As of Jun '26, AbbVie traded at a price-to-earnings ratio of about 101.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.